title: The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?
authors.affiliation: INSERM U 289, Hôpital de la Salpêtrière, Paris, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Agid
authors.forename: A M
authors.initials: AM
authors.lastname: Graybiel
authors.forename: M
authors.initials: M
authors.lastname: Ruberg
authors.forename: E
authors.initials: E
authors.lastname: Hirsch
authors.forename: J
authors.initials: J
authors.lastname: Blin
authors.forename: B
authors.initials: B
authors.lastname: Dubois
authors.forename: F
authors.initials: F
authors.lastname: Javoy-Agid
mesh_terms: D001921:Brain / Q000187:drug effects*; D001931:Brain Mapping; D003342:Corpus Striatum / Q000187:drug effects; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008134:Long-Term Care; D009434:Neural Pathways / Q000187:drug effects; D018377:Neurotransmitter Agents / Q000378:metabolism*; D010300:Parkinson Disease / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000187:drug effects*; D017981:Receptors, Neurotransmitter / Q000187:drug effects*; D013378:Substantia Nigra / Q000187:drug effects
chemical_list: D018377:Neurotransmitter Agents; D011954:Receptors, Dopamine; D017981:Receptors, Neurotransmitter; D007980:Levodopa